6.
Brooks C, Gu W
. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006; 21(3):307-15.
PMC: 3737769.
DOI: 10.1016/j.molcel.2006.01.020.
View
7.
Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti K
. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006; 10(2):99-111.
DOI: 10.1016/j.ccr.2006.06.016.
View
8.
Ikeda H, Old L, Schreiber R
. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002; 13(2):95-109.
DOI: 10.1016/s1359-6101(01)00038-7.
View
9.
Lin X, Yu H, Fang L, Tan Y, Liu Z, Wu D
. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. Elife. 2021; 10.
PMC: 8641947.
DOI: 10.7554/eLife.70715.
View
10.
Liu Y, Pan B, Qu W, Cao Y, Li J, Zhao H
. Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer. Cancer Cell Int. 2021; 21(1):130.
PMC: 7903729.
DOI: 10.1186/s12935-021-01833-y.
View
11.
Shi J, Liu J, Tu X, Li B, Tong Z, Wang T
. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer. 2022; 10(1).
PMC: 8804705.
DOI: 10.1136/jitc-2021-003133.
View
12.
Gao J, Yang D, Cao R, Huang H, Ma J, Wang Z
. The role of Fbxo5 in the development of human malignant tumors. Am J Cancer Res. 2022; 12(4):1456-1464.
PMC: 9077063.
View
13.
Oura K, Morishita A, Tani J, Masaki T
. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci. 2021; 22(11).
PMC: 8198390.
DOI: 10.3390/ijms22115801.
View
14.
Zimm S, Collins J, ONeill D, Chabner B, Poplack D
. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983; 34(6):810-7.
DOI: 10.1038/clpt.1983.254.
View
15.
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C
. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol. 2012; 44(3):365-73.
DOI: 10.1016/j.humpath.2012.03.030.
View
16.
Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z
. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization. Front Immunol. 2021; 12:754961.
PMC: 8530014.
DOI: 10.3389/fimmu.2021.754961.
View
17.
Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y
. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2017; 19(1):76-84.
PMC: 5832354.
DOI: 10.1038/s41590-017-0004-z.
View
18.
Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M
. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020; 48(W1):W449-W454.
PMC: 7319546.
DOI: 10.1093/nar/gkaa379.
View
19.
Rodrigo Mora J, Iwata M, von Andrian U
. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2009; 8(9):685-98.
PMC: 2906676.
DOI: 10.1038/nri2378.
View
20.
Villanueva A
. Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462.
DOI: 10.1056/NEJMra1713263.
View